Therapeutic efficacy of lysophosphatidylcholine in severe infections caused by Acinetobacter baumannii

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 7, 2015, Pages 3920-3924

  Smani, Younes ^a   Domínguez Herrera, Juan ^a   Ibáñez Martínez, José ^b   Pachóna, Jerónimo ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; LYSOPHOSPHATIDYLCHOLINE; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE;

ACINETOBACTER BAUMANNII; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL CLEARANCE; BACTERIAL INFECTION; BACTERIAL STRAIN; BLOOD CULTURE; COLONY FORMING UNIT; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE SEVERITY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; LD50; LETHALITY; LUNG; MORTALITY; MOUSE; MURINE MODEL; NONHUMAN; PERITONEAL SEPSIS; PNEUMONIA; PRIORITY JOURNAL; SEPSIS; SPECTROPHOTOMETRY; SPLEEN; ACINETOBACTER INFECTIONS; ANIMAL; ANTIBIOTIC RESISTANCE; BACTERIAL COUNT; BLOOD; C57BL MOUSE; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANIMALS; COLONY COUNT, MICROBIAL; CYTOKINES; DRUG RESISTANCE, BACTERIAL; FEMALE; LUNG; LYSOPHOSPHATIDYLCHOLINES; MICE; MICE, INBRED C57BL; MICROBIAL SENSITIVITY TESTS; PNEUMONIA; SEPSIS; SPLEEN;

EID: 84931275151     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.04986-14     Document Type: Article

References (28)

1. Mesquita RD, Carneiro AB, Bafica A, Gazos-Lopes F, Takiya CM, Souto-Padron T, Vieira DP, Ferreira-Pereira A, Almeida IC, Figueiredo RT, Porto BN, Bozza MT, Graca-Souza AV, Lopes AH, Atella GC, Silva-Neto MA. 2008. Trypanosoma cruzi infection is enhanced by vector saliva through immunosuppressant mechanisms mediated by lysophosphatidylcholine. Infect Immun 76:5543-5552. http://dx.doi.org/10.1128/IAI.00683-08.
2. Quinn MT, Parthasarathy S, Steinberg D. 1988. Lysophosphatidylcholine: a chemotactic factor for human monocytes and its potential role in atherogenesis. Proc Natl Acad Sci USA85:2805-2809. http://dx.doi.org/10.1073/pnas.85.8.2805.
3. Sakai M, Miyazaki A, Hakamata H, Sasaki T, Yui S, Yamazaki M, Shichiri M, Horiuchi S. 1994. Lysophosphatidylcholine plays an essential role in the mitogenic effect of oxidized low density lipoprotein on murine macrophages. J Biol Chem 269:31430-31435.
4. Lauber K, Bohn E, Krober SM, Xiao YJ, Blumenthal SG, Lindemann RK, Marini P, Wiedig C, Zobywalski A, Baksh S, Xu Y, Autenrieth IB, Schulze-Osthoff K, Belka C, Stuhler G, Wesselborg S. 2003. Apoptotic cells induce migration of phagocytes via caspase-3-mediated release of a lipid attraction signal. Cell 113:717-730. http://dx.doi.org/10.1016/S0092-8674(03)00422-7.
5. Yan JJ, Jung JS, Lee JE, Lee J, Huh SO, Kim HS, Jung KC, Cho JY, Nam JS, Suh HW, Kim YH, Song DK. 2004. Therapeutic effects of lysophosphatidylcholine in experimental sepsis. Nat Med 10:161-167. http://dx.doi.org/10.1038/nm989.
6. Hayakawa M, Ishida N, Takeuchi K, Shibamoto S, Hori T, Oku N, Ito F, Tsujimoto M. 1993. Arachidonic acid-selective cytosolic phospholipase A2 is crucial in the cytotoxic action of tumor necrosis factor. J Biol Chem 268:11290-11295.
7. Voelkel-Johnson C, Thorne TE, Laster SM. 1996. Susceptibility to TNF in the presence of inhibitors of transcription or translation is dependent on the activity of cytosolic phospholipase A2 in human melanoma tumor cells. J Immunol 156:201-207.
8. Conde G, Garcia-Barreno P, Municio AM, Suarez A. 1981. In vitro and in vivo effect of Escherichia coli endotoxin on mitochondrial phospholipase A2 activity. FEBS Lett 127:115-120. http://dx.doi.org/10.1016/0014-5793(81)80355-9.
9. Durkin JP, Shier WT. 1981. Staphylococcal delta toxin stimulates endogenous phospholipase A2 activity and prostaglandin synthesis in fibroblasts. Biochim Biophys Acta 663:467-479. http://dx.doi.org/10.1016/0005-2760(81)90175-2.
10. Kirschnek S, Gulbins E. 2006. Phospholipase A2 functions in Pseudomonas aeruginosa-induced apoptosis. Infect Immun 74:850-860. http://dx.doi.org/10.1128/IAI.74.2.850-860.2006.
11. Rodríguez-Baño J, Cisneros JM, Fernández-Cuenca F, Ribera A, Vila J, Pascual A, Martínez-Martínez L, Bou G, Pachón J. 2004. Clinical features and epidemiology of Acinetobacter baumannii colonization and infection in Spanish hospitals. Infect Control Hosp Epidemiol 25:819-824. http://dx.doi.org/10.1086/502302.
12. Vila J, Pachón J. 2012. Therapeutic options for Acinetobacter baumannii infections: an update. Expert Opin Pharmacother 13:2319-2336. http://dx.doi.org/10.1517/14656566.2012.729820.
13. Smani Y, Docobo-Pérez F, López-Rojas R, Domínguez-Herrera J, Ibáñez-Martínez J, Pachón J. 2012. Platelet-activating factor receptor initiates contact of Acinetobacter baumannii expressing phosphorylcholine with host cells. J Biol Chem 287:26901-26910. http://dx.doi.org/10.1074/jbc.M112.344556.
14. Smani Y, Docobo-Pérez F, McConnell MJ, Pachón J. 2011. Acinetobacter baumannii-induced lung cell death: role of inflammation, oxidative stress and cytosolic calcium. Microb Pathog 50:224-232. http://dx.doi.org/10.1016/j.micpath.2011.01.008.
15. Choi CH, Lee EY, Lee YC, Park TI, Kim HJ, Hyun SH, Kim SA, Lee SK, Lee JC. 2005. Outer membrane protein 38 of Acinetobacter baumannii localizes to the mitochondria and induces apoptosis of epithelial cells. Cell Microbiol 7:1127-1138. http://dx.doi.org/10.1111/j.1462-5822.2005.00538.x.
16. Smani Y, López-Rojas R, Domínguez-Herrera J, Docobo-Pérez F, Marti S, Vila J, Pachon J. 2012. In vitro and in vivo reduced fitness and virulence in ciprofloxacin-resistant Acinetobacter baumannii. Clin Microbiol Infect 18:E1-E4. http://dx.doi.org/10.1111/j.1469-0691.2011.03695.x.
17. th ed. National Academies Press, Washington, DC.
18. Smani Y, Domínguez-Herrera J, Pachón J. 2013. Association of the outer membrane protein Omp33 with fitness and virulence of Acinetobacter baumannii. J Infect Dis 208:1561-1570. http://dx.doi.org/10.1093/infdis/jit386.
19. López-Rojas R, Docobo-Pérez F, Pachón-Ibáñez ME, de la Torre BG, Fernández-Reyes M, March C, Bengoechea JA, Andreu D, Rivas L, Pachón J. 2011. Efficacy of cecropin A-melittin peptides on a sepsis model of infection by pan-resistant Acinetobacter baumannii. Eur J Clin Microbiol Infect Dis 30:1391-1398. http://dx.doi.org/10.1007/s10096-011-1233-y.
20. O'Reilly T, Cleeland R, Squires EL. 1996. Evaluation of antimicrobials in experimental animal infections, p 604-765. In Lorian V (ed), Antibiotics in laboratory medicine. Williams and Wilkins, Baltimore, MD.
21. Usansky JL, Desai A, Tang-Liu D. 2012. PK functions for Microsoft Excel. Department of Pharmacokinetics and Drug Metabolism, Allergan, Irvine, CA. Accessed 1 July 2012.
22. Pachón-Ibáñez ME, Docobo-Pérez F, López-Rojas R, Domínguez- Herrera J, Jiménez-Mejias ME, Garcia-Curiel A, Pichardo C, Jiménez L, Pachón J. 2010. Efficacy of rifampin and its combinations with imipenem, sulbactam, and colistin in experimental models of infection caused by imipenem-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 54:1165-1172. http://dx.doi.org/10.1128/AAC.00367-09.
23. Tokumura A. 2002. Physiological and pathophysiological roles of lysophosphatidic acids produced by secretory lysophospholipase D in body fluids. Biochim Biophys Acta 1582:18-25. http://dx.doi.org/10.1016/S1388-1981(02)00133-6.
24. Zhao Y, Natarajan V. 2013. Lysophosphatidic acid (LPA) and its receptors: role in airway inflammation and remodeling. Biochim Biophys Acta 1831:86-92. http://dx.doi.org/10.1016/j.bbalip.2012.06.014.
25. Cho WH, Park T, Park YY, Huh JW, Lim CM, Koh Y, Song DK, Hong SB. 2012. Clinical significance of enzymatic lysophosphatidylcholine (LPC) assay data in patients with sepsis. Eur J Clin Microbiol Infect Dis 31:1805-1810. http://dx.doi.org/10.1007/s10096-011-1505-6.
26. Drobnik W, Liebisch G, Audebert FX, Frohlich D, Gluck T, Vogel P, Rothe G, Schmitz G. 2003. Plasma ceramide and lysophosphatidylcholine inversely correlate with mortality in sepsis patients. J Lipid Res 44: 754-761. http://dx.doi.org/10.1194/jlr.M200401-JLR200.
27. Garnacho J, Sole-Violan J, Sa-Borges M, Diaz E, Rello J. 2003. Clinical impact of pneumonia caused by Acinetobacter baumannii in intubated patients: a matched cohort study. Crit Care Med 31:2478-2482. http://dx.doi.org/10.1097/01.CCM.0000089936.09573.F3.
28. McConnell MJ, Actis L, Pachón J. 2013. Acinetobacter baumannii: human infections, factors contributing to pathogenesis and animal models. FEMS Microbiol Rev 37:130-155. http://dx.doi.org/10.1111/j.1574-6976.2012.00344.x.